Tripos, Cara Therapeutics form research collaboration in area of neuropathic pain

By Lisa Kerner

Erie, Pa., March 22 - Tripos Discovery Research Ltd. said it has formed a research collaboration with Cara Therapeutics.

Terms of the agreement were not disclosed, according to a company news release.

Tripos Discovery Research will work in partnership with Cara's project team to support its drug discovery programs, focusing on the development of novel molecules.

"I am confident in Tripos' capabilities to accelerate discovery programs," Cara chief executive officer and president Dr. Derek Chalmers said in the release.

"Tripos' domain expertise in this therapeutic area complements our own, and we look forward to a fruitful partnership."

"We are delighted that Cara has selected Tripos Discovery Research to support its efforts to discover new medicines in the area of neuropathic pain," Tripos Discovery Research's senior vice president and managing director Dr. Mark Allen added.

"The therapeutic options currently available to treat these debilitating conditions are very limited. This relationship, which leverages a component of our G-protein-coupled receptor (GPCR) LeadDiscovery library, underscores the high value attributed to our expertise and therapeutic medicinal chemistry capabilities."

Tripos, based in Bude, England, delivers chemistry-research products and services for the biotechnology, pharmaceutical and other life science industries.

Cara, a biotechnology company based in Tarrytown, N.Y., is focused on developing novel therapeutics for pain and inflammation.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.